NCT03636906: A trial that was reported late by GlaxoSmithKline
This trial has reported, although it was 482 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03636906 |
|---|---|
| Title | A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 8, 2019 |
| Completion date | Jan. 16, 2020 |
| Required reporting date | Jan. 15, 2021, midnight |
| Actual reporting date | May 13, 2022 |
| Date last checked at ClinicalTrials.gov | April 25, 2025 |
| Days late | 482 |